Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. Available from.
   PubMed Web of Science ®Google Scholar
• Capocaccia R, Sant M, Berrino F, et al. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol. 2007;102(8):1661–1670. Available from.
   PubMed Web of Science ®Google Scholar
• Sarveazad A, Agah S, Babahajian A, et al. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci. 2019;24:86. Available from.
   PubMed Web of Science ®Google Scholar
• Chen XP, Qiu FZ, Wu ZD, et al. Long-term outcome of resection of large hepatocellular carcinoma. Br J Surg. 2006;93(5):600–606. Available from.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Guerra N, Fessas P, et al. Immune-based therapies for hepatocellular carcinoma. Oncogene. 2020;39:3620–3637. Available from.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci A, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol. 2021;17(7):755–757. Available from.
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de La Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88. Available from.
   PubMed Web of Science ®Google Scholar
• Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564–e204564. Available from.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. Available from.
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30:v874–v875. Available from.
   Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202. Available from.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci A, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021;13(8):637–644. Availale from.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. Available from
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2021;39(3_suppl):267. Available from.
   Web of Science ®Google Scholar
• Ren Z, Fan J, Xu J, et al. LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2. Ann Oncol. 2020;31:S1287. Available from.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. Available from.
   PubMed Web of Science ®Google Scholar
• Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020;72(2):342–352. Available from.
   PubMed Web of Science ®Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63. Available from.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck‑Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–693. Available from.
   PubMed Web of Science ®Google Scholar
• Kanzaki H, Chiba T, Ao J, et al. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Sci Rep. 2021;11(1):1–12. Available from.
   PubMed Web of Science ®Google Scholar
• Kim RD, Sarker D, Meyer T, et al. First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9(12):1696–1707. Available from.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2(1):1–23. Available from.
   Google Scholar
• Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–1239.e4. Available from.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Portela A, Sayols S, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015;61(6):1945–1956. Available from.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(6):1–28. Available from.
   PubMedGoogle Scholar
• Sia D, Jiao Y, Martinez-Quetglas I, et al.Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153(3):812–826. Available from
   PubMed Web of Science ®Google Scholar
• Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4(1):1–7. Available from.
   Google Scholar
• Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Gen. 2015;47(5):505–511. Available from.
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–235. Available from.
   PubMed Web of Science ®Google Scholar
• de Galarreta M R, Bresnahan E, Molina-Sánchez P, et al.β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–1141. Available from
   PubMed Web of Science ®Google Scholar
• Luke JJ, Bao R, Sweis RF, et al. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25(10):3074–3083. Available from.
   PubMed Web of Science ®Google Scholar
• Morita M, Nishida N, Sakai K, et al. Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. Liver Cancer. 2021;10:380–393.
   PubMed Web of Science ®Google Scholar
• Haber PK, Torres-Martin M, Dufour J-F, et al. Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. J Clin Oncol. 2021;39(15_suppl):4100.
   Web of Science ®Google Scholar
• Von Felden J, Craig AJ, Garcia-Lezana T, et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene. 2021;40(1):140–151. Available from.
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382–386. Available from.
   PubMed Web of Science ®Google Scholar
• Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73(6):1460–1469. Available from.
   PubMed Web of Science ®Google Scholar
• Yin Z, Ma T, Lin Y, et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J Cell Biochem. 2018;119(11):9419–9432. Available from.
   PubMed Web of Science ®Google Scholar
• Yu MC, Chen CH, Liang X, et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology. 2004;40(6):1312–1321. Available from.
   PubMed Web of Science ®Google Scholar
• Kassel R, Cruise MW, Iezzoni JC, et al. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology. 2009;50(5):1625–1637. Available from.
   PubMed Web of Science ®Google Scholar
• Qin W, Hu L, Zhang X, et al. The diverse function of PD-1/PD-L1 pathway beyond cancer. Front Immunol. 2019;10:2298. Available from.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zheng L, Du Q, et al. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother. 2020;69(9):1891–1903. Available from.
   PubMed Web of Science ®Google Scholar
• Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201–1217. Available from.
   PubMed Web of Science ®Google Scholar
• Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491–3494.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. Available from.
   PubMed Web of Science ®Google Scholar
• Kythreotou A, Siddique A, Mauri FA, et al. PD-L1. J Clin Pathol. 2018;71(3):189–194. Available from.
   PubMedGoogle Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Can Res. 2020;10(3):727–742. Available from: PMID: 32266087.
   PubMed Web of Science ®Google Scholar
• Kim HD, Song GW, Park S, et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma. Gastroenterology. 2018;155(6):1936–1950.e17. Available from.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–362. Available from.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. Available from.
   PubMed Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34(34):4102–4109. Available from.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. Available from.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. Available from.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. Available from.
   PubMed Web of Science ®Google Scholar
• Shah MA, Adenis A, Enzinger PC, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase 3 KEYNOTE-181 study. J Clin Oncol. 2019;37(15_suppl):4010. Available from.
   Web of Science ®Google Scholar
• Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971–979. Available from.
   PubMed Web of Science ®Google Scholar
• Feun LG, Li YY, Wu C, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer. 2019;125(20):3603–3614. Available from.
   PubMed Web of Science ®Google Scholar
• Liu GM, Li XG, Zhang YM. Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell Int. 2019;19(1):22. Available from.
   PubMedGoogle Scholar
• Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology. 2016;64(6):2038–2046. Available from.
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–820. Available from.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Mauri FA, Spina P, et al.Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the blueprint-HCC study. Br J Cancer. 2019;120(11):1033–1036. Available from
   PubMed Web of Science ®Google Scholar
• L-C L, Lee Y-H, Chang C-J, et al. Increased expression of programmed death-ligand 1 in infiltrating immune cells in hepatocellular carcinoma tissues after sorafenib treatment. Liver Cancer. 2019;8(2):110–120. Available from.
   PubMed Web of Science ®Google Scholar
• L-C L, Hsu C, Shao -Y-Y, et al. Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma. Liver Cancer. 2019;8(6):480–490. Available from.
   PubMed Web of Science ®Google Scholar
• Vilain RE, Menzies AM, Wilmott JS, et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res. 2017;23(17):5024–5033. Available from.
   PubMed Web of Science ®Google Scholar
• Fessas P, Spina P, Boldorini RL, et al. Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. Cancers (Basel). 2021;13(9):2137. Available from.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res. 2019;25(2):515–523. Available from.
   PubMed Web of Science ®Google Scholar
• Efremova M, Finotello F, Rieder D, et al. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol. 2017;8:1679. Available from.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. Available from.
   PubMed Web of Science ®Google Scholar
• Boyiadzis MM, Kirkwood JM, Marshall JL, et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. Journal for ImmunoTherapy of Cancer. 2018;6(1):1–7. Available from.
   PubMedGoogle Scholar
• Ang C, Klempner SJ, Ali SM, et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019;10(40):4018–4025. Available from.
   PubMedGoogle Scholar
• Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019;4(6). Available from. DOI:https://doi.org/10.1172/jci.insight.126908.
   Google Scholar
• Vétizou M, Pitt JM, Daillère R, et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–1084. Available from
   PubMed Web of Science ®Google Scholar
• Wong CN, Fessas P, Dominy K, et al. Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int. 2021;41(1):192–203. Available from.
   PubMed Web of Science ®Google Scholar
• Tang X, Fan L, Chen G, et al. Higher level of tumor mutational burden and 11q13 amplification in Chinese hepatocellular carcinoma patients. Cancer Res. 2018;78(13_s):4349. Available from.
   Web of Science ®Google Scholar
• Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008;68(10):3551–3557. Available from.
   PubMed Web of Science ®Google Scholar
• Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer. 2014;14(12):786–800. Available from.
   PubMed Web of Science ®Google Scholar
• Eso Y, Shimizu T, Takeda H, et al. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2020;55(1):15–26. Available from.
   PubMed Web of Science ®Google Scholar
• Lee V, Murphy A, Le DT, et al. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21(10):1200–1211. Available from.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl Med. 2015;372(26):2509–2520. Available from.
   PubMed Web of Science ®Google Scholar
• Goumard C, Desbois-Mouthon C, Wendum D, et al. Low levels of microsatellite instability at simple repeated sequences commonly occur in human hepatocellular carcinoma. Cancer Genomics Proteomics. 2017;14:329–339. Available from.
   PubMed Web of Science ®Google Scholar
• Kawaoka T, Ando Y, Yamauchi M, et al. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. Hepatol Res. 2020;50(7):885–888. Available from.
   PubMed Web of Science ®Google Scholar
• Ando Y, Yamauchi M, Suehiro Y, et al. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. Clin J Gastroenterol. 2020;13(5):867–872. Available from.
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Bryant C, et al. Dendritic cells as pharmacological tools for cancer immunotherapys. Pharmacol Rev. 2015;67(4):731–753. Available from.
   PubMed Web of Science ®Google Scholar
• Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10(2):99–111. Available from.
   PubMed Web of Science ®Google Scholar
• Sheppard S, Ferry A, Guedes J, et al. The paradoxical role of NKG2D in cancer immunity. Front Immunol. 2018;9:1808. Available from.
   PubMed Web of Science ®Google Scholar
• Sun H, Huang Q, Huang M, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology. 2019;70(1):168–183. Available from.
   PubMed Web of Science ®Google Scholar
• Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012;18(18):4997–5007. Available from.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25(7):2116–2126. Available from.
   PubMed Web of Science ®Google Scholar
• Ding W, Xu X, Qian Y, et al. Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2018;97(50):e13301. Available from.
   PubMed Web of Science ®Google Scholar
• Chew V, Chen J, Lee D, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012;61(3):427–438. Available from.
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al.NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–456. Available from
   PubMed Web of Science ®Google Scholar
• Kelley RK, Grete TF. Hepatocellular carcinoma - origins and outcomes. N Engl J Med. 2021;385(3):280–282. Available from.
   PubMed Web of Science ®Google Scholar
• Hectors S, Lewis S, Besa C, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol. 2020;30(7):3759–3769. Available from.
   PubMed Web of Science ®Google Scholar
• Naqash AR, Kihn-Alarcón AJ, Stavraka C, et al. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. Ann Transl Med. 2021;9(12):1034. Available from.
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Greten TF. Gut microbiome in HCC – mechanisms, diagnosis and therapy. J Hepatol. 2020;72(2):230–238. Available from.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Helmink BA, Spencer CN, et al. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33(4):570–580. Available from.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–1089. Available from.
   PubMed Web of Science ®Google Scholar
• Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–1379. Available from.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7(1). Available from. DOI:https://doi.org/10.1186/s40425-019-0650-9.
   Google Scholar
• Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69:1867–1876. Available from.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397–411. Available from
   PubMed Web of Science ®Google Scholar
• Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97–101. Available from.
   PubMed Web of Science ®Google Scholar
• Galloway-Peña JR, Smith DP, Sahasrabhojane P, et al. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Med. 2017;9(1):21. Available from.
   PubMed Web of Science ®Google Scholar
• David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–563. Available from.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–970. Available from.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Tucci M, Adamo V, et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020;8(2):1361. Available from.
   PubMed Web of Science ®Google Scholar
• Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39:2008–2023. Available from.
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. Available from.
   PubMed Web of Science ®Google Scholar
• Roxburgh CSD, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–163. Available from.
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Dam WA, Hospers GAP, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283–287. Available from.
   PubMedGoogle Scholar
• Mano Y, Shirabe K, Yamashita YI, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013;258(2):301–305. Available from.
   PubMed Web of Science ®Google Scholar
• Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58–64. Available from.
   PubMed Web of Science ®Google Scholar
• Chan SL, Chan AWH, Chan AKC, et al. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver Int. 2017;37(2):280–289. Available from.
   PubMed Web of Science ®Google Scholar
• Dharmapuri S, Özbek U, Lin J, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy. Cancer Med. 2020;9(14):4962–4970. Available from.
   PubMed Web of Science ®Google Scholar
• Muhammed A, Fulgenzi CAM, Dharmapuri S, et al. The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. Cancers (Basel). 2022;14:186. Available from.
   Web of Science ®Google Scholar
• Zheng YB, Zhao W, Liu B, et al. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev. 2013;14(9):5527–5531. Available from.
   PubMedGoogle Scholar
• Carr BI, Guerra V, de Giorgio M, et al. Small hepatocellular carcinomas and thrombocytopenia. Oncology. 2012;83(6):331–338. Available from.
   PubMed Web of Science ®Google Scholar
• Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci. 2013;58(6):1790–1796. Available from.
   PubMed Web of Science ®Google Scholar
• Singal AG, Hoshida Y, Pinato DJ, et al. International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology. 2021;160(7):2572–2584.
   PubMed Web of Science ®Google Scholar
• Fessas P, Naeem M, Marron TU, et al. Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study. In: Proceedings of the 112th Annual Meeting of the American Association for Cancer Research; 2021 Apr 10-15. Philadelphia (PA): AACR; 2021. Abstract nr 485.
   Google Scholar
• Kelley RK. Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial. ESMO Virtual Plenary. 2021 November 20.
   Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA2022. 40(4_suppl): 379–379.
   Google Scholar